NeuroBo Pharmaceuticals, Inc. (NRBO) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Boston, MA, 美国. 现任CEO为 Hyung-Heon Kim.
NRBO 拥有 IPO日期为 2016-08-05, 8 名全职员工, 在 NASDAQ Capital Marke, 市值为 $20.33M.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
